Substantial doubt about the company's ability to continue as a going concern.
“The Company's existing cash and cash equivalents are not sufficient to fund operating plans for at least one year from the issuance date of these financial statements. Accordingly, these conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Gossamer Bio, Inc. stockholders approved potential common stock issuances exceeding 20% under the August 20, 2026 securities purchase agreement at the October 27, 2026 special meeting.
On September 25, 2026, Gossamer Bio received Nasdaq notice that it regained compliance with the minimum bid price requirement, closing the matter. The company effected a 1-for-80 reverse stock split on September 10, 2026, and split-adjusted trading began on September 11, 2026.
Gossamer Bio, Inc. submitted its first NDA in September 2026 to the U.S. Food and Drug Administration for seralutinib to treat pulmonary arterial hypertension, supported by Phase 3 PROSERA and Phase 2 TORREY findings; filing acceptance could occur later this year.
